DNTH Stock Forecast & Price Target

Dianthus Therapeutics is well-positioned to become a leader in the development of next-generation therapies for severe autoimmune diseases with their strong team of experienced executives and promising pipeline, including the potentially game-changing Claseprubart. Recent updates to their pipeline, such as narrowing the timing for the Phase 2 MMN study and disclosing development indications for DNTH212, indicate progress and potential market opportunities. Despite potential risks, we remain bullish on DNTH's potential and have adjusted our target to $105, driven by increased pricing assumptions and accelerated launch timing for Claseprubart.

Dianthus Therapeutics is a clinical-stage biotechnology company with a solid team of experienced executives and a promising pipeline. However, their 1Q26 financials were in-line and they will need additional funding to complete development and commercialization of their assets. In addition, their upcoming CAPTIVATE interim data release may be limited due to trial integrity, and while there is potential for positive results, even positive results on par with competitor riliprubart could be a win for them. Thus, the current uncertainties surrounding DNTH's financials and upcoming data release make for a negative outlook on their stock.